Target intelligence / Profile preview

Midasin AAA ATPase 1 (MDN1)

Target
MDN1
Molecular classification
Enzyme (ATPase, specifically a AAA ATPase: ATPase associated with diverse cellular activities), Other (Macromolecular ribosome biogenesis factor: acts as a nuclear chaperone)
01

Overview

Midasin AAA ATPase 1 (MDN1) is a massive, essential ATPase enzyme that functions as a nuclear chaperone for the large subunit of the eukaryotic ribosome. MDN1 utilizes ATP hydrolysis to power ATP-fueled motions that physically restructure and remove assembly factors from pre-60S ribosomal particles, a key step in ribosome biogenesis. Structurally, MDN1 contains a ring-shaped AAA ATPase domain, extended linking domains, and a C-terminal MIDAS (Metal Ion-dependent Adhesion Site) domain. The MIDAS domain is responsible for binding substrate proteins (assembly factors), transmitting mechanical force to facilitate their removal via dynamic conformational coupling with the AAA ring. MDN1 is not a druggable target in current pharmacology but is studied via chemical inhibitors like Rbin-1 to dissect ribosome assembly mechanisms. Dysfunction or mutation of MDN1 can disrupt ribosome formation and is implicated in rare human disorders, but it is not an established therapeutic or disease target

Other names
MidasinKIAA0301Dynein-related AAA-ATPase MDN1MIDAS-containing proteinRea1midasin homologMdn1
02

Mechanism of action

Noncompetitive, allosteric inhibition of ATPase activity by Rbin-1 (binds and induces conformational change, affecting the coupling between the AAA ring and the MIDAS domain; used only in research, not a therapeutic mechanism)

03

Biological functions

Ribosome biogenesis (specifically, assembly and maturation of the large ribosomal 60S subunit)Removal of assembly factors from ribosomal precursors (remodeling pre-60S subunits through ATP hydrolysis and mechanochemical force)Regulation of nuclear export of pre-60S ribosomal subunits
04

Disease associations

Other (MDN1 mutations associated with some inherited disorders, but no direct, validated role in common therapeutic areas; weak associations with Long QT syndrome and autism spectrum disorder are described in human genetics but are not well established)
05

Safety considerations

None reported in a clinical or therapeutic context (no drugs target this protein in patients; its essential function in ribosome biogenesis suggests likely toxicity if inhibited systemically)
06

Interacting drugs

Rbin-1 (experimental small molecule; not a marketed drug, used as a chemical probe tool in research to inhibit Mdn1 ATPase activity)

Beyond the preview

Go deeper on Midasin AAA ATPase 1 (MDN1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Midasin AAA ATPase 1 (MDN1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call